AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04111406
Drug: Protocol based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural insertion and epidural drug administration depend on anesthetist in research team using protocol based~1. insertion at mid-level of surgical insertion~2. insertion depth is 3-5 cm in space, not more than 5 cm~3. using benzoin tincture and transparent dressing to fix catheter~4. test dose with 2%xylocaine with adrenaline 1:200,000 3ml If not cover desired dermatome: 2% lidocaine with adr added 3 ml every 5 min (up to 2 times)~5. After induction and patients' hemodynamic are stable. Load 2 mg morphine with 0.0625% bupivacaine + morphine 0.02 mg/ml 3 ml then continuous infusion with rate according to initial local anesthetic requirement for incisional area coverage
Trial: NCT01833533
Drug: ABT-450/r/ABT-267, ABT-333
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
Trial: NCT00158756
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for the Rotarix™ vaccine
Trial: NCT03949244
Drug: Normal saline 0.9%
RxNorm normalized name: BD Posiflush Normal Saline 0.9% Prefilled Syringe Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 0.9% will be applied to the nailfold and images of the blood flow in the nailfold capillaries will be acquired.
Trial: NCT00605735
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, placebo, once daily, 12 weeks
Trial: NCT00343239
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Formulation: infusion solution~Route of administration: IV infusion on the first day of each 21-day cycle~Dose regimen: 750 mg/m2/day for 5 days
Trial: NCT02017730
Drug: [11C]BMT-136088
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01799863
Drug: Ketorolac trometamol 0.45% with carboxymethylcellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01799863
Drug: Preservative free artificial tear
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02677181
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: short-term methotrexate
Trial: NCT00166036
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12 Weeks of Oral Pravastatin 80 mg therapy.
Trial: NCT00127036
Drug: XELOX
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: XELOX: Oxaliplatin 130 mg/m\^2 intravenously (IV); Capecitabine 825 mg/m\^2 by mouth (po)
Trial: NCT00127036
Drug: XELIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XELIRI: Irinotecan 240 mg/m\^2 IV; Capecitabine 825 mg/m\^2 by mouth (po)
Trial: NCT01543191
Drug: PUR118
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low dose and high dose for 3 doses, BID
Trial: NCT00662610
Drug: naproxen 250 mg - 500mg -750 mg bid
RxNorm normalized name: naproxen 750 MG
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: naproxen 250 mg - 500mg -750 mg bid
Trial: NCT01600859
Drug: Placebo for E2609
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules~According to the randomized study design, participants who are assigned to receive placebo will each receive a single dose consisting of two capsules of placebo
Trial: NCT04281979
Drug: Study Agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study agent will be administered via beverages and/or a capsule. The substances used in the study are legal, non-prescription, and are proven safe for human consumption at the doses used. The study agent may be a depressant (such as alcohol), a stimulant (such as caffeine), or an analgesic (such as aspirin).
Trial: NCT03361345
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Vehicle is going to be a cream without any active medication that will be applied as a control substance for the topical tranexamic acid cream, and will be applied to the contralateral side of the face.
Trial: NCT04281979
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the placebo conditions participants will consume beverages and capsules that contain no or very small quantities of the study agent.
Trial: NCT02105792
Drug: second- or third-line glucose-lowering diabetes treatment
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation of response and disease progression following clinician's addition of a glucose-lowering diabetes therapy (Sulphonylurea, DPP-4 inhibitor, GLP-1R agonist, SGLT2 inhibitor or Glitazone) to existing therapy.
Trial: NCT04655872
Drug: [14C]TPN171H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single 10 mg oral dose of \[14C\]TPN171H containing approximately 100 microcurie of \[14C\]-TPN171H.
Trial: NCT01836406
Drug: Ketorolac tromethamine and remote ischemic preconditioning
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketorolac tromethamine/ single / 1mg/kg/ intravenous administration 30 min before renal artery clamping, remote ischemic preconditioning / 200 mmHg / 5 min inflation and 10 min deflation / 3 cycles / after anesthetic induction
Trial: NCT03560349
Drug: placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be prescribed a regimen of 1 g acetaminophen q 8hrs alternating with 600 mg ibuprofen q 6 hours. In addition they will be instructed to continue oral fluid hydration and minimal activity for 24 hours.~At 2-hours following the SPG blockade an EBP will be offered to patients. Patient will also be informed that they can request an EBP at any time. The SPG blockade will be performed twice daily in the hospital and twice daily at home, by the patient. The patient will also be informed, if that at anytime, they would like an EBP, it can be provided.~While the study is being conducted, patients will not be offered a SPG block unless enrolled in the study.
Trial: NCT01832935
Drug: Insulin NPH
RxNorm normalized name: insulin NPH human isophane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The starting dose of insulin NPH was 24 units per day (0.2-0.6 unit/kg) in 2 divided doses
Trial: NCT03028740
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cenicriviroc placebo-matching, tablet, orally, once daily for up to approximately 40 months.
Trial: NCT00070057
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT03058419
Drug: Caffeine 50 mg
RxNorm normalized name: caffeine 50 MG
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive caffeine 50 mg tablet (1\*50 mg) orally as a drug cocktail on Day 1, 7 and 11.
Trial: NCT05369468
Drug: Bupivacain only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: to assess efficacy of bupivacain alone in ultrasound-guided erector spinae plane block in patient undergoing laporoscopic cholecystectomy. primary outcome was the total amount of morphine consumption in the first 24-hour postoperative, and the secondary outcomes were the time of first rescue analgesia ,pain score, and safety.
Trial: NCT03651466
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will receive a single dose of either GX-G6 or placebo in randomized fashion.
Trial: NCT02566993
Drug: Doxorubicin (DOX)
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02566993
Drug: Cyclophosphamide (CTX)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03274882
Drug: S95005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment is given in open manner. It was administered until unacceptable toxicity according to the investigator, disease progression or patient withdrawal. If a patient discontinues study treatment for reasons other than radiologic disease progression (e.g., intolerable side effects), the patient was followed for tumour response until radiologic disease progression or initiation of new anticancer therapy (whichever occurs first).
Trial: NCT01912638
Drug: Provisc
RxNorm normalized name: Provisc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provisc is an cohesive viscoelastic.
Trial: NCT00535587
Drug: Placibo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02255682
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02998450
Drug: Placebo Oral Capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsule with 50 mg microcrystalline cellulose in capsules identical to those used for the active pharmaceutical ingredient.
Trial: NCT01524250
Drug: corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1250mg of oral prednisone daily for 3 days
Trial: NCT01524250
Drug: corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000mg IV methylprednisolone daily for 3 days
Trial: NCT02003911
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin suspension (200mg/5mL)
Trial: NCT02003911
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00669071
Drug: Fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied once daily at bedtime on one side of the face; this was a randomized, split face study where one cream was used on the right side of the face and the other cream on the left side of the face and IPL (Intense Pulsed Light) was used on both sides of the face.
Trial: NCT00669071
Drug: Cetaphil® Moisturizing Cream as Inactive Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied once daily at bedtime on the opposite side of the face; this was a randomized, split face study where one cream was used on the right side of the face and the other cream on the left side of the face and IPL (Intense Pulsed Light) was used on both sides of the face.
Trial: NCT01635062
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive placebo for 3 weeks.
Trial: NCT03123861
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to this arm will receive 2 weeks of placebo post-operatively..
Trial: NCT04156620
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects will receive i.v. placebo at randomization (BSL visit), Weeks 4, 8, and 12 , followed by the administration of secukinumab 3 mg/kg i.v. at Week 16 and every four weeks through Week 48 (exposure through Week 52)
Trial: NCT01346774
Drug: Placebo powder capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 placebo capsules twice a day
Trial: NCT02441244
Drug: Visbiome
RxNorm normalized name: Visbiome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visbiome probiotic
Trial: NCT03582280
Drug: Amorphous Calcium Carbonate (ACC) - Amor
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amor Powder is composed of Amorphous Calcium Carbonate and is administered oral Amor Inhaled Double Pack is composed of 1% ACC in solution and is administered by inhalation
Trial: NCT02024373
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg (every evening orally) for 8 weeks
Trial: NCT01929031
Drug: ibuprofen + caffeine
RxNorm normalized name: caffeine / ergotamine / ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC tablet
Trial: NCT01929031
Drug: ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: tablet.
Trial: NCT01929031
Drug: ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: tablet
Trial: NCT01963403
Drug: EE 30mcg/LNG 150mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 pill per day; daily during study participation (up to 84 days)
Trial: NCT01963403
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 pill per day; daily during study participation (up to 84 days)
Trial: NCT01929031
Drug: caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT01929031
Drug: ibuprofen + caffeine
RxNorm normalized name: caffeine / ergotamine / ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed Dose Combination (FDC) tablet
Trial: NCT01929031
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT03596931
Drug: Statins (Cardiovascular Agents)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescribed with statins
Trial: NCT01435226
Drug: placebo to match RBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribovirin placebo BID
Trial: NCT02394730
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill taken orally once daily for 12 weeks
Trial: NCT02222324
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 placebo tablets matching E2609
Trial: NCT01946074
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil, Folinic acid and Irinotecan will be administered by intravenous infusion.
Trial: NCT01946074
Drug: ABT-165
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-165 will be administered by intravenous infusion at escalating dose levels.
Trial: NCT00507546
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nightly 8mg of placebo (same appearance as ramelteon)
Trial: NCT00145639
Drug: Ifosfamide, Carboplatin, Doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See Detailed Description for treatment plan.
Trial: NCT01565616
Drug: Conditioning Regimen with Bone Marrow Transplant
RxNorm normalized name: Sus scrofa bone marrow preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The bone marrow transplant regimen is below. Day 0 is the day of the transplant. The - sign is the number of days before and the + sign is the number of days after the transplant.~Day -8 BU 3.2 mg/ kg/dose IV~Day -7 BU 3.2 mg/kg/dose IV, FLU 35mg/m2 IV~Day -6 BU 3.2 mg/kg/dose IV, FLU 35mg/m2 IV, ATG 0.5mg/kg IV~Day -5 BU 3.2 mg/kg/dose IV, FLU 35mg/m2 IV, ATG 1.0mg/kg IV~Day -4 FLU 35mg/m2 IV, ATG 1.5mg/kg IV~Day -3 FLU 35mg/m2 IV, ATG 1.5mg/kg IV~Day -2 ATG 1.5mg/kg IV~Day -1 Rest~Day 0 Stem cell infusion~Graft Versus Host Disease (GVHD) Regimen~Day -3 Calcineurin Inhibitor (Cyclosporine or Tacrolimus) therapeutic doses through day 180, then taper~Day 0 Stem cell infusion~Day +1 Methotrexate 7.5 mg/m2 IV~Day +3 Methotrexate 7.5 mg/m2 IV~Day +6 Methotrexate 7.5 mg/m2 IV~Day+11 Methotrexate 7.5 mg/m2 IV
Trial: NCT02243839
Drug: Thrombolytic Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy is performed to the patients with obstructive prosthetic valve thrombosis
Trial: NCT02523196
Drug: HepQuant-SHUNT (Drug and Device) #65,123 (4D-cholate) and IND #65,121 (13C-cholate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The HQ-SHUNT test is being evaluated for safety and effectiveness as an alternative to Hepatic Venous Pressure Gradient (HVPG) testing in patients with liver disease
Trial: NCT02031016
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: fentanyl bolus injections on an as needed base, NEXT TO the fentanyl bolus injections on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium.
Trial: NCT02031016
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: starting with 0.15 ug/IBW(kg)/min, next to fentanyl bolus injections (200-500 ug) on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium.
Trial: NCT02031016
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: fentanyl bolus injections on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium.
Trial: NCT04019184
Drug: L-Alanyl/L-Glutamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediately after randomization (not longer than 30 min after fulfilling eligibility criteria), patients will receive intravenous infusions with the investigational drug
Trial: NCT04019184
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediately after randomization (not longer than 30 min after fulfilling eligibility criteria), patients will receive intravenous infusions with the placebo
Trial: NCT04469621
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:capsule Route of administration: oral
Trial: NCT00809159
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to AIN457
Trial: NCT03983252
Drug: [F-18]PBR06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET radiopharmaceutical
Trial: NCT03033836
Drug: ARV treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir 50 mg QD plus co-formulated emtricitabine 200 mg/tenofovir 300 mg QD.
Trial: NCT00400621
Drug: acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00856973
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet per day for 12 weeks
Trial: NCT00409318
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC q week
Trial: NCT00773734
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03642353
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children will be included in a cross-over study with control of plaque using Triclosan/placebo toothpaste for 4 months. Each child will be tested for placebo toothpaste for 45 days and for Triclosan toothpaste for more 45 days. At the beginning of each test, they will be included in a washout period with placebo toothpaste for 15 days.
Trial: NCT06227624
Drug: Oral zinc sulfate and standard phototherapy
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: study the role of oral zinc sulfate in reducing level of indirect hyperbilirubinemia in neonates if used with standard phototherapy
Trial: NCT02765217
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison the effects of Lactobacillus reuteri DSM 17938 and placebo for prevention of antibiotic associated diarrhea and also plan to compare the duration of treatment for on
Trial: NCT02328222
Drug: ESW group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CORTICOSTEDORID TREATMENT WAS AS FOLLOWS: day zero post-transplantation (DP 0), 500 mg/day of MPD; (DP 1), 250 mg MPD; (DP 2), 125 mg MPD; (DP 3), 60 mg MPD; (DP 4), 30 mg MPD; and (DP 5), PREDNISONE AS DOSES 1 MG/KG (1 MONTH) AND A REDUCTION TO ACHIEVE 0.1 MG/KG IN THE 3rd MONTH.
Trial: NCT01880125
Drug: Tramadol HCI/Acetaminophen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test drug: Tramadol HCI/Acetaminophen 75/650mg, two times daily. Reference drug: Tramadol HCI/Acetaminophen 37.5/325 mg, four times daily.
Trial: NCT00358748
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: See detailed description above.
Trial: NCT00872885
Drug: GRT6005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liquid formulation, 200 to 600 µg, single dose, one day
Trial: NCT00872885
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dosage
Trial: NCT03161548
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All eligible subjects will receive ICT with DCU regimen every 21 days as follows:~Docetaxel 36 mg/m2 intravenous infusion over 1 hr, followed by Cisplatin 30 mg/m2 intravenous infusion over 1 hr, on day 1 and day 8, Oral tegafur/uracil 300 mg/m2/day plus leucovorin 90 mg/day on days 1 - 14
Trial: NCT00084448
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01612039
Drug: ASP3291
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, 1,000 mg (four 250-mg tablets), twice a day, 8 weeks
Trial: NCT01612039
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets
Trial: NCT04051463
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo eye drops instilled once daily
Trial: NCT00650442
Drug: Estradiol Transdermal System Placebo - Alternate Adhesive
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single application
Trial: NCT00650442
Drug: Estradiol Transdermal System Placebo - Current Adhesive
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single application
Trial: NCT00531050
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose indacaterol matching placebo via Concept 1 device